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Summary A panel of 73 samples, including 52 primary breast carcinomas, 10 normal breast tissues and 11
axillary lymph nodes, has been analysed for the presence of amplifications and gross structural alterations, in
the oncogenes c-erbB-2, c-erbA, c-myc, N-myc, c-mos and c-Ha-ras. The tumours were also classified, graded
and staged histopathologically and their DNA ploidy (42 samples) was determined by flow cytometry. Three
breast cancer cell lines (MCF7, ZR-75-1 and T47D) were also included in the study. Amplification of c-erbB-2
was detected in 28% of the tumours, of which 91% had an increased steady-state level of c-erbB-2 mRNA.
Amplification of c-erbA was found in 23% of tumours and was always associated with the amplification of
c-erbB-2. Ten out of 12 (83%) tumours which had c-erbB-2 and c-erbA co-amplification had metastasised to
axillary lymph nodes (P<0.006). However, the human thymidine kinase gene, which is present at the same
chromosomal location as these two oncogenes (17q21-22), was amplified in only two tumours. Amplification
of c-myc was detected in 21% of the tumours studied, of which 82% (P<0.005) were of histopathological
grade 3 and none were of grade 1. Flow cytometry showed that 90% (P<0.01) of the analysed tumours with
c-erbB-2 and c-erbA co-amplification, and 70% (P<0.1) of those with c-myc amplification were DNA
aneuploid. This study demonstrates the potential value of c-myc amplification in the assessment of the tumour
grade, rather than metastatic potential; and of the co-amplification of c-erbB-2 and c-erbA as a strong
indicator of metastatic potential, rather than tumour grade.
Abnormalities in either the structure or activity of proto-
oncogenes can contribute to the development or progression
of the malignant phenotype (Slamon et al., 1984; Nishimura
& Sekiya, 1987). Several studies have shown that cellular
oncogenes are activated in breast tumours. For example c-
myc has been found both amplified and over-expressed in
human breast carcinoma (Escot et al., 1986; Varley et al.,
1987; Mariani-Costantini et al., 1988), and the loss of c-Ha-
ras-I alleles has been demonstrated in 27% of breast tumours
from patients constitutionally heterozygous for this allele
(Theillet et al., 1986; Ali et al., 1987). A number of studies
have also reported the presence of c-erbB-2 amplification and
over-expression in primary breast tumours (Slamon et al.,
1987; Venter et al., 1987; Varley et al., 1987; Zhou et al.,
1987; Berger et al., 1988; Gusterson et al., 1988a, b; Barnes et
al., 1988; van de Vijver et al., 1987, 1988), and breast tumour
cell lines (Kraus et al., 1987; van der Vijver et al., 1987).
These studies have demonstrated correlations between c-
erbB-2 amplification and regional lymph node metastasis and
poor prognosis (Slamon et al., 1987; Zhou et al., 1987;
Varley et al., 1987) and/or tumour grade (Berger et al., 1988;
Barnes, et al., 1988).
The c-erbB-2 and c-erbB-1 (epidermal growth factor recep-
tor) are distinct but related genes and are both homologous
to the v-erb-B oncogene of avian erythroblastosis virus
(AEV) (Semba et al., 1985; Schechter et al., 1985; Yamamoto
et al., 1986). The other oncogene of AEV, v-erb-A, is the
homologue of c-erbA, one of the steroid receptor family of
genes, encoding a nuclear receptor for thyroid hormone
(Weinberger et al., 1986). In the human genome both c-erbA
and c-erbB-2 are located on chromosome 17q21-22 (Fukus-
hige et al., 1986; Yamamoto et al., 1986; Weinberger et al.,
1986). The close proximity of these two genes, the co-exis-
tence of their viral homologues in AEV, and the clear evi-
dence of co-operation between v-erb-A and v-erb-B onco-
genes (Frykberg et al., 1983; Sealy et al., 1983) all point to
possible co-operation between the oncogenically activated
c-erbB-2 and c-erbA in the process of malignant transforma-
tion.
The purpose of this study was to identify possible altera-
tions in either the structure or expression of a number of
oncogenes (myc, mos, ras, erbB-2 and erb-A), in human
breast carcinomas and breast tumour cell lines. For controls
we have also analysed the thymidine kinase (TK) gene which
is on the same chromosomal location as c-erbB-2 and c-erbA,
and the dihydrofolate reductase (DHFR) gene which is lo-
cated on chromosome Sq 11-13. Flow cytometric analysis of
tumour and lymph node tissue was also performed in order
to compare the relationship between gene amplifications and
gross DNA abnormalities.
Materials and methods
Fresh excision biopsy or mastectomy specimens containing
primary carcinomas from 52 patients were dissected to pro-
vide representative samples which were either rapidly frozen
and stored in liquid nitrogen, for subsequent DNA and RNA
extraction, or fixed and processed for morphological and
flow cytometric studies. When available, material from axil-
lary lymph node metastases was also examined and in 10
cases normal breast tissue from the specimen was used to
provide a normal control. The tumours were classified ac-
cording to standard criteria (Page et al., 1987). There were 42
infiltrating ductal, five infiltrating lobular, one tubular, two
mucinous and two cribriform ductal carcinomas. Tumour
grading was performed by the method of Bloom and Rich-
ardson, as modified by Elston (Elston, 1987). The three
mammary tumour cell lines used were, MCF7 ZR-75-1 and
T47D (Kraus et al., 1987; van de Vijver et al., 1987).
DNAflow cytometry
Nuclear DNA measurements were performed on sections cut
from paraffin embedded material from tumour and axillary
nodes using a modification of the method of Hedley et al.,
(1983), as described in detail previously (Quirke et al., 1986).
DNA extraction and hybridisation
High molecular weight DNA was isolated according to stan-
dard procedures. DNA samples (7jig) were then digested
with the restriction endonucleases EcoRl, HindlII or BamHI,
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separated by gel electrophoresis using 0.7% agarose gels,
transferred on to Hybond nylon filters and hybridised to32P
oligo-labelled probes (Feinberg & Vogelstein, 1983). Hyb-
ridisation, washing and reprobing of the filters were con-
ducted as recommended by the manufacturers. The level of
amplification in each sample was quantified by densitometric
scanning of the autoradiographs using a Joyce Loebel micro-
densitometer. As a control for the equal loading, transfer and
hyridisation of the DNA samples, the blots were stripped and
re-hybridised with probes for TK and DHFR. The intensities
of the TK and DHFR hybridising fragments were used as
references for normalisation of the results.
RNA isolation and slot blot analysis
The level of c-erbB-2 RNA was determined in the three cell
lines' 14 tumours (in which sufficient tissue was available),
one positive lymph node and one peripheral blood lym-
phocyte sample. Caesium chloride gradient centrifugation
was used to isolate the RNA (Tavassoli & Shall, 1988). In
the tumour samples from which both RNA and DNA were
isolated a single extraction procedure was used (Chirgwin et
al., 1979). Ten pg samples of total RNA were used for slot
blot analysis (Darling et al., 1989). The filters were then
sequentially hybridised to the 32P-labelled c-erbB-2 and c-
erbA probes. The level ofP-actin RNA was used to standar-
dise the relative amount of RNA loaded in each sample. The
level of each RNA species was quantitated by scanning den-
sitometry of the autoradiographs.
Probes
The following probes were used. The c-erbB-2 probe was a
4.6 kb Sal-Hind III cDNA fragment isolated from the plas-
mid pSV2neuT (Bargmann et al., 1986). The c-erbA probe
was the 2.4 kb EcoRI-Hindll fragment of pHE-AI plasmid
(Jansson et al., 1983). For the detection of c-myc we used the
1.3 kb ClaI-EcoRI fragment of pmyc plasmid, containing
c-myc exon 3 (Dalla-Favera et al., 1982). The N-myc probe
was the EcoRI-BamHI insert of the plasmid pNB-I (Schwab
et al., 1983). The c-Ha-ras probe was the 2.9 kb SstI frag-
ment from the plasmid pHA-l (Chang et al., 1982). The TK
probe was a 1.3 kb SmaI-BamHI fragment isolated from
pTKl 1 (Bradshaw & Deininger, 1984). The DHFR probe
was the 1.8 kb EcoRI fragment from pBH31R-1.8 (Yang et
al., 1984). The mos probe was the 1.0 kb HindIII-XbaI
fragment of molony murine sarcoma virus, isolated from the
plasmid pmos31 (Verma et al., 1980). The beta-actin probe
was a 1.1 kb PstI fragment from pAL41, provided by Dr P.
Barton (Pasteur Institute, Paris).
Results
Amplification ofc-erbB-2, c-erbA and c-myc
Hybridisation with the c-erbB-2 cDNA probe showed
amplification in 15 of the 52 tumour samples (Figure 1 and
Tables I and II), but there was no evidence of gross genomic
rearrangements. The degree of amplification ranged from
4-fold in tumour T50 to 40-fold in tumour T35 (Figure la).
Rehybridisation of these blots with the c-erbA probe detected
between 3 and 40-fold amplification in 12 of the 52 tumours
(Figure lb). Neither the c-erbB-2 nor c-erbA probes detected
any amplification in the non-malignant breast tissues from
the same patients (10 non-malignant tissues examined). Only
two of the eight positive lymph nodes had c-erbB-2 and
c-erbA amplification (L25 and L45, see Table I). However,
the level ofamplification was much lower in the lymph nodes
than in the corresponding tumours. None of the three
negative lymph nodes had amplification of either c-erbB-2 or
c-erbA (data not shown). It is interesting to note that c-erbA
amplification was present only in the tumour samples in
which the c-erbB-2 gene was also amplified. However, in
tumour T26 only the 2.1 kb BamH1 fragment of c-erbB-2
was amplified (approximately 4-fold, compared with the
2.2 kb N-myc fragment in the BamHl digest-data not
shown). By contrast c-erbB 2 amplification was detected in
three tumours (Figure 1, T36 and T49; T12 not shown)
which did not contain c-erbA amplification.
The analysis of the TK gene, which is on the same
chromosomal location as c-erbB-2 and c-erbA (17q21-22),
was used to determine the extent of the amplified domain on
chromosome 17. TK amplification was detected in two sam-
ples only (Figure ld, T35 and T45). Interestingly, these were
tumours in which the highest levels of c-erbB-2 and c-erbA
amplification were detected.
The re-hybridisation of the same filters with the c-myc
probe demonstrated the amplification of c-myc gene (located
on chromosome 8q24) in 11 of the 52 tumours (Figure Ic).
The level of c-myc amplification in these samples varied
between 3 (T47) and 15-fold (T26). Three of the tumours
(T26, T45 and T50) in which c-myc was amplified also had
both c-erbB-2 and c-erbA amplification; in tumour T49 c-myc
and c-erbB-2 were amplified but not c-erbA (Figure 1). Three
of these (T26, T45 and T49) were grade 3 tumours, with
positive lymph nodes. Rehybridisation of these samples with
the appropriate probes for c-Ha-ras (chromosome lIpIS),
N-myc (chromosome 2q23-24) and c-mos (chromosome
8q22) did not detect the amplification of these genes in any
of the 73 samples analysed (data not shown). The absence of
c-mos amplification demonstrates that the c-myc amplified
domain (8q24) does not extend to the c-mos locus (8q22) in
any of the analysed samples. These blots were finally probed
for DHFR (chromosome Sqll-13), which detected no
amplification in any of the samples and confirmed the
presence of equal amounts of DNA in each track (data not
shown). This is also indicated by the comparison of the
intensity of the c-myc and TK hybridising bands in Figure Ic
and d.
Although there was no evidence of c-Ha-ras amplification
in any of the tissues, in two of the seven samples in which
BamHl restriction fragment length polymorphism suggested
c-Ha-ras heterozygosity in the non-malignant tissue, there
was clear evidence of homozygosity for this locus in the
tumour (Figure 2). Approximately 50% of all tumours
analysed were homozygous for the c-Ha-ras locus, but since
non-tumour tissue was available only in 10 cases, it was not
possible to determine what proportion of the homozygosity
in the other samples was a result of allelic deletions from a
heterozygous background.
c-erbB-2 and c-erbA RNA expression
The steady-state level of c-erbB-2 transcripts was elevated 3
to 15-fold in 11 tumours in which the gene was also found to
have been amplified (Figure 3a). The level of c-erbB-2 RNA
appears to correlate with the level of gene amplification in
these tumours: no increase in the RNA level was detected in
any of the tumours without gene amplification (Figure 3, T2
and T40). However, two cell lines, ZR-75-1 and T47D, which
did not appear to have c-erbB-2 amplification, both showed
about 10-fold higher levels of c-erbB-2 transcripts than was
detected in MCF7.
The c-erbA probe did not detect over-expression in any of
the tumours with the possible exception of a 2-fold increase
in one tumour (Figure 3b and Table I, T24). To eliminate the
possibility of loading errors in these studies the slot blots
were finally stripped and rehybridised to the beta-actin
probe. A similar level of beta-actin RNA was detected in all
samples (Figure 3c), thus demonstrating that the detected
variations in the steady-state level of c-erbB-2 and c-erbA
were not due to differences in the amount of RNA applied to
the slot-blots.
Clinical correlation
Comparison of the available clinical data, such as tumour
grade, lymph node involvement, tumour size and ploidy, with
the analysis ofalterations in either the structure or expressionc-erbB-2/c-erbA CO-AMPLIFICATION 507
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Figure 1 Amplification of c-erbB-2, c-erbA and c-myc genes in human breast carcinomas. DNA samples from breast tumour (T),
normal breast (N), lymph nodes (L) were digested with restriction enzyme EcoRI or BAM HI and hybridised to probes for c-erbB-2 (a),
c-erbA (b), c-myc (c) and TK (d).
Table I c-erbB-2 and c-erbA gene amplification and RNA levels
Sample Gene copy number Increase in RNA level
no. c-erbB-2 c-erbA c-erbB-2 c-erbA
T5 10 5 3 1
T12 5 1 n.d. n.d.
T14 20 10 10 I
T17 15 10 5 1
T23 25 25 15 1
T24 25 25 4 2
T25 15 15 4 1
L25 4 4 n.d. n.d.
T26 4 5 n.d. n.d.
T33 15 15 1 1
T35 40 40 10 I
T36 5 1 10 I
T45 30 30 10 1
L45 5 5 n.d. n.d.
T46 25 25 10 1
T49 5 1 n.d. n.d.
T50 4 3 4 1
Numbers indicate the level ofgene amplification and the increase in
the level of RNA above normal (1 indicates the normal level).
n.d., not done.
of the oncogenes examined, suggests a statistically significant
correlation between c-myc amplification and tumour grade
(P<0.005) (Tables II and IV). Amplification of c-myc was
detected in 45% of all grade 3 tumours, but in only 8% of
the grade 2 tumours. No c-myc amplification was detected in
any of nine grade I tumours. There is a similar correlation
between c-myc amplification and tumour grade in tumours
with positive axillary lymph nodes (Table III).
In the tumours with positive axillary lymph nodes, only
one of the 18 grade I and 2 tumours (5%) had c-myc
amplification, but in five of the seven (71%) grade 3 tumours
c-myc was amplified between 3 and 15-fold. Nine of the 11
(82%) tumours with c-myc amplification were of histo-
pathological grade 3 (Table IV).
By contrast to c-myc, the amplification of c-erbB-2 appears
to be correlated best with tumour metastasis rather than
grade (P<0.025). Eleven of 15 (73%) tumours with c-erbB-2
amplification (between 4 and 40-fold) were node positive
(Table IV). This correlation is particularly impressive in
tumours with both c-erbB-2 and c-erbA amplification
(P<0.006); 10 of 12 (83%) such tumours were node positive.
Only six of 11 (54%) node positive tumours showed c-myc
amplification (Table IV). Flow cytometry showed that nine
of 10 (90%) tumours with c-erbB-2/c-erbA co-amplification
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Table II Oncogene amplification in breast tumours: all cases
Tumour DNA
grade No. aneuploid c-erbB-2 c-erbA c-myc N-myc c-mos
1 9 3/7 (43%) 4/9 (44%) 4/9 (44%) 0/9 (0%) 0/9 0/9
2 23 10/20 (50%) 4/23 (17%) 2/23 (8%) 2/23 (8%) 0/23 0/23
3 20 9/15 (60%) 7/20 (35%) 6/20 (30%) 9/20 (45%) 0/20 0/20
Total 52 22/42 (52%) 15/52 (29%) 12/52 (23%) 11/52 (21%) 0/52 0/52
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Figure2 c-Ha-rasanalysisin breast tumours. DNA samplesfrom a
number of tumours (T), non-tumour tissues (N), and normal
lymphocytes (Lm) were digested with BamHI and hybridised to a
c-Ha-ras probe.
and seven of 10 (70%) tumours with c-myc amplification
were DNA aneuploid (Table IV).
Discussion
The results presented here demonstrate two patterns of
oncogene amplification. Co-amplification-of c-erbB-2 and c-
erbA appears to be related to the presence of axillary node
metastasis, while c-myc amplification appears to correlate
well with high tumour grade. There is also evidence of c-Ha-
ras allelic deletion in two of seven tumours in which
heterozygosity could be confirmed in normal tissue. Whether
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Figure 3 Slot blot analysis of a c-erbB-2 and c-erbA RNA level.
10 lgoftotal RNA from tumours (T) one lymph node (L) and from
peripheral blood lymphocytes of a healthy individual (Lm) were
denatured and hybridised toc-erbB-2 (a), c-erbA (b) andP-actin (c).
a, b and c were exposed for 24, 72 and 4 hours respectively.
the latter finding could suggest the possible involvement of
recessive oncogenes or tumour suppressors in the develop-
ment of breast tumours is not at present clear.
The detected c-erbB-2 gene amplification correlates with
previous work which has suggested a relationship between
c-erbB-2 amplification, poor prognosis and lymph node
invovlement in breast tumour patients (Slamon et al., 1987;
Varley et al., 1987; Zhou et al., 1987; Berger et al., 1988). In
the present study we demonstrated that the presence of c-
erbA co-amplification in breast tumours, only reported by
van de Vijver et al. (1987), is associated with a greater chance
ofaxillary node metastasis. However, it is important to stress
that the converse may not be true. That is, the absence of
Table Ill Oncogene amplification in breast tumours with positive axillary nodes
Tumour DNA
grade No. aneuploid c-erbB-2 c-erbA c-myc N-myc c-mos
1 7 3/5 (60% 4/7 (57%) 4/7 (57%) 0/7 (0%) 0/7 0/7
2 11 7/10(71%) 2/11 (18%) 2/11 (18%) 1/11 (9%) 0/11 0/11
3 7 3/5 (60%) 5/7 (71%) 4/7 (57%) 5/7 (71%) 0/7 0/7
Total 25 13/20 (65%) 11/25 (44%) 10/25 (40) 6/25 (24%) 0/25 0/25
Table IV Analysis of tumours with oncogene amplification
Amplified Metastatic/total (ratio) Grade 3/total (ratio) Aneuploid/total (ratio)
oncogene P P P
c-myc 6/11 (54%) n.s. 9/11 (82%) <0.005 7/10 (70%) n.s.
c-erb-B-2 11/15 (73%) <0.025 7/15 (46%) n.s. 7/12 (58%) n.s.
c-erb-A/c-erbB-2 10/12 (83%) <0.005 6/12 (50%) <0.025 9/10 (90%) <0.01
n.s., not significant.c-erbB-2/c-erbA CO-AMPLIFICATION 509
c-erbB-2/c-erbA co-amplification does not necessarily indicate
the absence of lymph node metastasis; in 14 of the node
positive tumours examined there was no evidence of either
c-erbB-2 or c-erbA amplification.
It is interesting to note that c-erbA amplification was
present only in tumour samples with c-erbB-2 amplification,
suggesting that the latter may have in fact caused or cont-
ributed to the amplification of c-erbA, which happens to be
located on the same chromosomal domain. This co-
amplification in metastasising breast tumours agrees well
with the known properties of the two viral homologues of
these genes. The first, v-erb-B, is both necessary and suf-
ficient for the initiation and maintenance of cellular transfor-
mation in chick embryo fibroblasts and erythroid cells
(Frykberg et al., 1983; Sealy et al., 1983). The second, v-erb-
A which by itself is devoid of any transforming activity,
co-operates with the v-erb-B, resulting in the formation of
transformed cells of increased malignancy and metastatic
ability. Whether the c-erbA amplification is only a fortuitous
consequence of its close proximity to the amplified c-erbB-2
gene, as suggested by van der Vijver et al. (1987), or whether
its amplification has any significance for the development
and progression of the breast tumour can not be determined
from the present study. However, the fact that the TK gene,
which is located on the same chromosomal domain, appears
to be amplified in only two tumours, both of which had the
highest level of erbB-2/erbA co-amplification, and the co-
operativity of these oncogenes in chicken fibroblasts and
erythroid cells, suggest that the co-amplification may have
contributed to the more aggressive nature of these tumours.
The presence of positive axillary lymph nodes in 10 of the 12
tumours (83%) with the c-erbB-2/c-erbA co-amplification
strengthens this notion.
Despite the good correlation between the c-erbB-2 and
c-erbA amplification, particularly in the metastatic breast
tumours, the molecular significance of this alteration for
tumour development and progression remains unclear. We
have not detected the over-expression of c-erbA in any of
the tumour samples (with the possible exception of tumour
T24) or the breast tumour cell lines. Whether this is due to
absence of increased expression or the failure of detection,
possibly due to the short half-life of the message, is not clear.
By contrast to the c-erbA, the amplification of c-erbB-2 was
associated with a 3 to 15-fold increase in c-erbB-2 RNA
levels; no increase in the c-erbB-2 RNA level was detected in
any of the breast tumours without the amplification. In-
creased steady-state c-erbB-2 mRNA and protein level and
their association with lymph node involvement, metastasis
and/or poor prognosis have also been reported (Venter et al.,
1987; van der Vijver et al., 1987; Berger et al., 1988). How-
ever, in two other studies a closer correlation was found
between increased c-erbB-2 protein level and tumour
pathogenesis, in particular with in situ ductal- carcinoma
(Gusterson et al., 1988a,b) and tumour size (van der Vijver et
al., 1988) rather than lymph node involvement.
In agreement with previously published data, in none of
the three breast tumour cell lines examined (MCF7,
ZR-75-1 and T47D) was there any evidence of either c-
erbB-2 or c-erbA amplification. Nevertheless, two of these
lines (ZR-75-1 and T47D) did have a much higher steady-
state level of c-erbB-2 RNA than MCF7 cells. However, we
note that van der Vijver et al. (1987) did not detect c-erbB-2
over expression in the T47D cells. The over-expression of
c-erbB-2, in the absence of gene amplification, has also been
detected in three other breast tumour cell lines (BT483,
MDA-MB175 and ZR-75-30) (Kraus et al., 1987). Therefore,
different mechanisms, one of which appears to be amplifica-
tion, could lead to the increased levels ofc-erbB-2 RNA. The
involvement of c-erbB-2 in breast tumours may not be
restricted only to those cases in which either amplification or
over-expression is detectable. It has been demonstrated that
the rat homologue of c-erbB-2, the neu oncogene, can be
activated by a point mutation altering a valine residue to a
glutamic acid residue in its predicted transmembrane domain
(Bargmann et al., 1986). We are currently investigating
whether such mutations are present in the c-erbB-2 gene of
either the MCF7 cell line or the tumour samples in which
neither amplification nor the over-expression of c-erbB-2 was
detected.
The analysis of the c-myc domain demonstrated amplifica-
tion in 21% of all breast tumours analysed in this study.
There appears to be no correlation between c-myc amplifica-
tion and lymph node metastasis. However, the fact that nine
of the 11 tumours (82%) with the c-myc amplification were
ofgrade 3, and that none of the grade 1 tumours showed any
evidence of c-myc amplification, does suggest a strong cor-
relation between tumour grade and c-myc amplification
(P<0.005). Escot et al. (1986) have also detected the amp-
lification of c-myc in human breast tumours but find a better
correlation with age rather than tumour grade (P<0.02).
However, Varley et al. (1987), who have also detected c-myc
amplification in human breast tumours, have not found such
a correlation with age (menopausal status), but demonstrate
a significant correlation between c-myc alteration (amplifica-
tion and/or rearrangement) and poor short-term prognosis
(P<0.02).
The study of the c-Ha-ras oncogene, which in in vitro
studies has been found to co-operate with the myc oncogene
in the malignant transformation of primary rodent fibrob-
lasts (Land et al., 1983), demonstrates the allelic deletion of
the c-Ha-ras in two of the seven tumours in which there was
clear evidence ofheterozygosity in this domain. Both of these
tumours were of grade 3, and one (T27) also showed 5-fold
amplifiction of the c-myc gene. The allelic deletion of c-Ha-
ras has also been detected in approximately 25% of all breast
tumours; about 74% of the tumours with the deletion were
grade 3 (Theillet et al., 1986; Ali et al., 1987). These studies
have found a good correlation between c-Ha-ras allelic dele-
tion and tumours of histopathological grade 3. As suggested
by these authors, the allelic deletion of c-Ha-ras
(chromosome I Ipl5) may be indicative of the possible
involvement of recessive oncogene (tumour suppressor
genes), including the Wilm's tumour gene which is located on
chromosome 1lpl3 (Koufos et al., 1984), in the aetiology of
breast tumours.
In conclusion, the studies reported here demonstrate a
good correlation between c-erbB-2/c-erbA co-amplification
and the metastatic ability of the breast tumours, while c-myc
amplification correlates well with high tumour grade, but not
metastasis.
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